Share ownership BioMarin Pharmaceutical Inc.

BMRN

US09061G1013

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 12:57:22 21/01/2026 am IST			5-day change	1st Jan Change
55.72 ^USD	+2.07%		+0.92%	-6.26%

06:55pm	Canaccord Genuity Upgrades BioMarin Pharmaceutical to Buy From Hold, Adjusts Price Target to $98 From $84	MT
06:51pm	Greenland, Tariffs, and the Quiet Revolt of the Bond Market

Share class: BioMarin Pharmaceutical Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	19,05,83,016	18,89,02,489 ( 99.12 %)	0	99.12 %

Major shareholders: BioMarin Pharmaceutical Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 9.96 %	1,91,35,228	9.96 %	1 137 M $
Vanguard Fiduciary Trust Co. 9.673 %	1,85,82,585	9.673 %	1 104 M $
PRIMECAP Management Co. 7.927 %	1,52,29,287	7.927 %	905 M $
Dodge & Cox 7.645 %	1,46,86,801	7.645 %	873 M $
STATE STREET CORPORATION 4.562 %	87,64,599	4.562 %	521 M $
Viking Global Investors LP 4.332 %	83,22,179	4.332 %	495 M $
AQR Capital Management LLC 3.088 %	59,32,109	3.088 %	353 M $
Geode Capital Management LLC 1.844 %	35,42,120	1.844 %	211 M $
Millennium Management LLC 1.368 %	26,27,210	1.368 %	156 M $
Capital Research & Management Co. (Global Investors) 1.321 %	25,37,596	1.321 %	151 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
BB Gestão de Recursos DTVM SA 0.000125 %	482	0.000125 %	14 643 $

Breakdown by shareholder type

Institutional	84.23%
Other	6.83%
State Street Corp.	4.56%
Individuals	0.72%
Schweizerische Nationalbank	0.29%
Swedbank AB	0.24%
Sumitomo Mitsui Trust Group, Inc.	0.24%
Governments	0.16%
SEI Investments Co.	0.13%
Manulife Financial Corp.	0.07%
Danske Bank A/S	0.06%
Skandinaviska Enskilda Banken AB	0.02%
Banque Cantonale Vaudoise	0.01%
The Bank of Nova Scotia	0.01%
Unknown	2.43%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	78.49%
United Kingdom	4.71%
France	2.65%
Norway	1.92%
Canada	1.71%
Australia	1.31%
Luxembourg	1.08%
Sweden	0.98%
Netherlands	0.92%
Individuals	0.72%
Japan	0.66%
Switzerland	0.6%
Denmark	0.54%
Ireland	0.3%
South Korea	0.29%
Germany	0.27%
Belgium	0.08%
Hong Kong	0.08%
Italy	0.05%
Finland	0.04%
Austria	0.04%
China	0.03%
United Arab Emirates	0.02%
Singapore	0.02%
South Africa	0.01%
Poland	0.01%
Spain	0.01%
Liechtenstein	0.01%
Slovenia	0.01%
Cayman Islands	0.01%

Based on 1000 largest holdings

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Employees

3,040

Sector

Pharmaceuticals

Calendar

25/02 - Q4 2025 Earnings Release (Projected)

More about the company